226400.KQ Osteonic Co. Ltd
- Market cap
- KRW 81.4B
- P/E
- 8.0x
- P/B
- 1.13x
- ROE
- 12.4%
- Dividend yield
- -
- Fundamental score
- 3.0/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 226400.KQ undervalued?
Graham number226400.KQ trades 36.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Osteonic Co. Ltd fundamental analysis
15 of 22 checks passedROE 1/2
Moderate return on equity (12.4%), between 10% and 20%.
ROA 1/1
Return on assets (7.9%) is above the industry median (1.4%).
Profit Consistency 1/2
Profitable for 4 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (31.0%) is above the industry median (1.8%).
Revenue Growth 2/2
Revenue grew 31.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (5.4%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 9.7x against interest expense, well covered.
PE vs Market 1/1
PE (8.0x) is below the market median (11.3x).
PE vs Industry 1/1
PE (8.0x) is below the industry median (11.4x).
PBV 0/1
Price to book (1.1x) is above the industry median (0.9x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 9.1, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Osteonic Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Osteonic Co. Ltd
Osteonic Co., Ltd. develops, manufactures, and sells bone fixation systems. It offers CMF systems, including neuro plating systems, maxillofacial plating systems, mandible plating systems, IMF screws, power screw drivers, 90 angled screw driver, customized neuro 3D mesh, and mandible reconstruction plates under the OPTIMUS and Real FIT brand names; and biodegradable CMF plating systems under the BIOBSORB name. The company also provides products for trauma and extremities, wh…
Full company profileOsteonic Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Osteonic Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.64B | 8.54B | 9.08B | 11.2B | 12.6B | 15.6B | 19.8B | 27.8B | 34.2B | 45.4B | 52.2B |
| Gross Profit | 4.00B | 4.87B | 3.92B | 5.03B | 5.50B | 6.50B | 8.73B | 13.1B | 16.7B | 22.1B | 25.3B |
| Operating Income | 1.26B | 1.91B | -3.31B | -191M | -2.51B | -503M | 2.53B | 4.35B | 6.83B | 8.86B | 9.50B |
| EBITDA | - | - | - | - | - | - | 5.87B | 5.24B | 11.0B | 13.3B | 16.9B |
| Net Income | 1.54B | -4.24B | -6.64B | 499M | -5.38B | -2.85B | 836M | 3.66B | 5.65B | 7.50B | 8.95B |
| EPS | 197 | -543 | -523 | 39 | -417 | -169 | 50 | 185 | 285 | 374 | 446 |
| Balance Sheet | |||||||||||
| Total Assets | 21.6B | 29.7B | 44.0B | 52.3B | 63.3B | 64.2B | 61.5B | 71.7B | 89.9B | 100B | 114B |
| Total Liabilities | 9.89B | 22.2B | 15.5B | 23.4B | 39.0B | 28.6B | 25.0B | 19.9B | 30.6B | 32.9B | 41.7B |
| Shareholders' Equity | 11.7B | 7.43B | 28.5B | 29.0B | 24.3B | 35.5B | 36.5B | 51.9B | 59.3B | 67.5B | 71.9B |
| Cash & Short-term Investments | 2.92B | 4.56B | 15.7B | 12.5B | 23.8B | 21.6B | 17.0B | 14.7B | 20.6B | 14.4B | 14.3B |
| Total Debt | - | - | - | 12.0B | 11.4B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.73B | -796M | 318M | -2.46B | 2.75B | 2.95B | 3.99B | 4.14B | 4.72B | 9.02B | 8.83B |
| Capital Expenditure | 3.20B | 1.10B | 5.26B | 5.95B | 949M | 939M | 481M | 6.97B | 7.05B | 8.95B | 21.0B |
| Free Cash Flow | - | - | - | - | -526M | -876M | 1.68B | -2.83B | -2.33B | 65.1M | -12.2B |
| Ratios | |||||||||||
| ROE | 13.2% | -57.2% | -23.3% | 1.7% | -22.2% | -8.0% | 2.3% | 7.1% | 9.5% | 11.1% | 12.4% |
| ROA | 7.1% | -14.3% | -15.1% | 1.0% | -8.5% | -4.4% | 1.4% | 5.1% | 6.3% | 7.5% | 7.9% |
| Net Profit Margin | 23.2% | -49.7% | -73.1% | 4.5% | -42.7% | -18.3% | 4.2% | 13.2% | 16.5% | 16.5% | 17.2% |
| Debt to Equity | - | - | - | 0.41x | 0.47x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Osteonic Co. Ltd dividends
Osteonic Co. Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1.5:1 on Jun 24, 2020.
Who owns Osteonic Co. Ltd
- Insiders 19.03%
- Institutions 0.93%
- Public & others 80.04%
- Shares outstanding 20.1M
- Free float 14.8M
Osteonic Co. Ltd company profile
- Company name
- Osteonic Co. Ltd
- Ticker
- 226400.KQ
- ISIN
- KR7226400000
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 205
- Fiscal year end
- December
- Address
- 1206Ho, 38, Digital-ro 29-gil, Seoul, South Korea
- Phone
- 82 2 6892 8430
- Website
- osteonic.com
About Osteonic Co. Ltd
Osteonic Co., Ltd. develops, manufactures, and sells bone fixation systems. It offers CMF systems, including neuro plating systems, maxillofacial plating systems, mandible plating systems, IMF screws, power screw drivers, 90 angled screw driver, customized neuro 3D mesh, and mandible reconstruction plates under the OPTIMUS and Real FIT brand names; and biodegradable CMF plating systems under the BIOBSORB name. The company also provides products for trauma and extremities, which include hand plating, wrist plating, foot plating, and hallux valgus systems, as well as cannulated screws under the SIGNEX name. In addition, it offers dental products, such as mini screws, GBR systems, palatal plates, power drivers, and palatal expanders under the Optimus D name; veterinary systems; and sports medicines under the KINEX brand name. The company serves physicians and university hospitals. Osteonic Co., Ltd. was founded in 2012 and is based in Seoul, South Korea.
Osteonic Co. Ltd management
10- Mr. DongWon LeeChief Executive Officer · born 1969
- Mr. Cheol-soo YoonSenior Executive Vice President · born 1969
- Mr. Chang-Ho MoonExecutive Director · born 1970
- Mr. Jeongnam ParkExecutive Director · born 1971
- Mr. Sangho SeoExecutive Director · born 1974
- Mr. Jun-gyu LeeExecutive Director · born 1978
- Mr. Dong-seon OhExecutive Director · born 1971
- Mr. JaeGeun ParkExecutive Director · born 1968
- Mr. Hyunjun ChoiExecutive Director · born 1974
- Mr. JungWoo ChaeExecutive Director · born 1977